Gene-Hacked immune cells take on tough cancers

NCT ID NCT05361174

Recruiting now Disease control Sponsor: Iovance Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after chemotherapy. The goal is to see if this personalized cell therapy is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IOV-4001 (a personalized cell therapy made from a patient's own tumor-fighting immune cells, genetically modified to remove the PD-1 checkpoint)
What this could lead to: If successful, this could offer a new treatment option for people with advanced melanoma or lung cancer who have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 53 participants, so results may not apply to everyone. The treatment involves intensive chemotherapy and carries risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchial neoplasm carcinoma lung disorder lung neoplasm melanoma metastatic melanoma neoplasm non-small cell lung carcinoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MELANOMA STAGE III NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER UNRESECTABLE MELANOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Medical College of Wisconsin
WITHDRAWN

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Orlando Health Cancer Institute
RECRUITING

Orlando, Florida, 32610, United States
Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States
The Angeles Clinic and Research Institute
RECRUITING

Los Angeles, California, 90025, United States
The University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45219, United States
University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
Weill Medical College of Cornell University
RECRUITING

New York, New York, 10022, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.